NASDAQ · INDP
Indaptus Therapeutics, Inc.
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
Loading market information…
NASDAQ · SPRC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
SciSparc Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.69% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow SciSparc Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
$0.53-$0.01 (-1.26%)
Jasper Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.55% below the high.
$2.31-$0.02 (-0.86%)
Artelo Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.71% below the high.
$0.84+$0.19 (+29.23%)
Salarius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.41% below the high.
$0.76-$0.15 (-16.31%)
Azitra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.08% below the high.
$0.59-$0.01 (-1.99%)
Onconetix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.71% below the high.
$0.65-$0.01 (-1.07%)
Protagenic Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.76% below the high.
$0.52-$0.02 (-2.92%)
Scinai Immunotherapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 96.65% below the high.
